Instil Bio, Inc. (TIL)
5.70
-0.07
(-1.21%)
USD |
NASDAQ |
Oct 22, 16:00
5.725
+0.02
(+0.44%)
After-Hours: 20:00
Instil Bio Enterprise Value : 56.15M for Oct. 22, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 22, 2026 | 56.15M |
| October 21, 2026 | 56.62M |
| October 20, 2026 | 57.77M |
| October 19, 2026 | 56.76M |
| October 16, 2026 | 57.57M |
| October 15, 2026 | 59.06M |
| October 14, 2026 | 57.84M |
| October 13, 2026 | 59.40M |
| October 12, 2026 | 62.11M |
| October 09, 2026 | 63.20M |
| October 08, 2026 | 61.98M |
| October 07, 2026 | 64.28M |
| October 06, 2026 | 64.18M |
| October 05, 2026 | 64.62M |
| October 02, 2026 | 66.45M |
| October 01, 2026 | 66.56M |
| September 30, 2026 | 66.59M |
| September 29, 2026 | 65.91M |
| September 28, 2026 | 65.23M |
| September 25, 2026 | 66.11M |
| September 24, 2026 | 65.78M |
| September 23, 2026 | 66.56M |
| September 22, 2026 | 65.84M |
| September 21, 2026 | 65.44M |
| September 18, 2026 | 65.57M |
| Date | Value |
|---|---|
| September 17, 2026 | 66.39M |
| September 16, 2026 | 66.18M |
| September 15, 2026 | 66.39M |
| September 14, 2026 | 68.01M |
| September 11, 2026 | 67.54M |
| September 10, 2026 | 67.40M |
| September 09, 2026 | 68.90M |
| September 08, 2026 | 70.52M |
| September 04, 2026 | 68.90M |
| September 03, 2026 | 69.44M |
| September 02, 2026 | 69.61M |
| September 01, 2026 | 69.64M |
| August 31, 2026 | 69.10M |
| August 28, 2026 | 68.90M |
| August 27, 2026 | 70.79M |
| August 26, 2026 | 70.59M |
| August 25, 2026 | 69.03M |
| August 24, 2026 | 70.46M |
| August 21, 2026 | 68.90M |
| August 20, 2026 | 67.88M |
| August 19, 2026 | 67.61M |
| August 18, 2026 | 67.06M |
| August 17, 2026 | 67.40M |
| August 14, 2026 | 67.54M |
| August 13, 2026 | 66.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.613B |
| Alnylam Pharmaceuticals, Inc. | 30.07B |
| Anika Therapeutics, Inc. | 269.09M |
| Savara, Inc. | 789.89M |
| Vericel Corp. | 2.131B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.299M |
| Total Expenses (Quarterly) | 4.299M |
| EPS Diluted (Quarterly) | -0.6339 |
| Earnings Yield | -78.46% |
| Normalized Earnings Yield | -79.27 |